Creative Medical Tech

Q3 FY2026 EarningsQ3 FY26 results missed consensus across all key profitability metrics, despite in-line zero revenue. Net loss of -$2.66M was significantly wider than the -$1.56M expected, driven by a 244% YoY surge in R&D expenses ($1.60M) and a 43% increase in SG&A ($1.11M). Diluted EPS of -$0.40 missed the -$0.24 consensus by 66.7%, primarily due to heavy stock-based compensation related to the BioDefense acquisition and clinical trial advancements.